CTRI/2010/091/001073已完成2 期
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily Pf-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control - Not Applicable
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ages Eligible for Study: 18 Years to 65 Years
- •Genders Eligible for Study: Both
- •Accepts Healthy Volunteers: No
- •1.Patients with type 2 diabetes and hypertension
- •2.Medically stable
- •3.On at least 1 (and up to 2) oral diabetes drugs
- •4.And up to 2 medicines for blood pressure control
排除标准
- •1.Patients with type 1 diabetes
- •2.Heart attack
- •4.Uncontrolled blood pressure
- •5.Significant kidney disease
研究者
相似试验
进行中（未招募）
1 期
Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: LLTClassification code 10067761Term: Exacerbation of idiopathic pulmonary fibrosisSystem Organ Class: 100000004855IDIOPATHIC PULMONARY FIBROSISEUCTR2016-003473-17-GRCelgene Corporation135
进行中（未招募）
1 期
Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: LLTClassification code 10067761Term: Exacerbation of idiopathic pulmonary fibrosisSystem Organ Class: 100000004855IDIOPATHIC PULMONARY FIBROSISEUCTR2016-003473-17-GBCelgene Corporation135
进行中（未招募）
1 期
A 12-Week, Phase 2, Randomized, Double-Blind,Placebo-Controlled Study of LY2599506 in Patientswith Type 2 Diabetes Mellitus Treated with Diet andExercise, with or without MetforminEstudio de fase 2, aleatorizado, doble ciego, de 12 semanas de duración, controlado con placebo, de LY2599506 en pacientes con diabetes mellitus tipo 2 tratados con dieta y ejercicio, con o sin metforminadiabetes mellitus tipo 2MedDRA version: 9Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-014958-16-ESilly S.A.120
进行中（未招募）
1 期
A 4 week study to evaluate the effectiveness and safety of GRC 17536 a new medication in patients with diabetes who have peripheral nerve involvementPain associated with diabetic peripheral neuropathy (DPN).MedDRA version: 20.0 Level: LLT Classification code 10012683 Term: Diabetic peripheral neuropathy System Organ Class: 100000004852EUCTR2012-002320-33-GBGlenmark Pharmaceuticals SA138
进行中（未招募）
不适用
A 4 week study to evaluate the effectiveness and safety of GRC 17536 a new medication in patients with diabetes who have peripheral nerve involvementPain associated with diabetic peripheral neuropathy (DPN).MedDRA version: 14.1Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-002320-33-DEGlenmark Pharmaceuticals SA138